RxDoctor Payments Data

Richard Frederick, MD

Gastroenterology · San Francisco, CANPI 1720009160

Payments from drug & device makers

$429,458in general payments, 2019–2025

Across 123 payments — averaging $3491.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$153K
  • Mallinckrodt Enterprises LLC$70K
  • Bausch Health US, LLC$67K
  • Mallinckrodt Hospital Products Inc.$66K
  • Madrigal Pharmaceuticals$57K
  • Intercept Pharmaceuticals, Inc.$12K
  • plus $4K from 7 others

What the payments were for

  • Consulting fees$69,98649%
  • Speaking & faculty fees$65,15546%
  • Travel & lodging$4,5713%
  • Food & beverage$2,7342%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$429,458 in reported general payments places this provider in the 95th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$164,391
Medicare patients
461
Services billed
1,066

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpclusaSofosbuvir/Velpatasvir18$422,141
XifaxanRifaximin122$402,504
VemlidyTenofovir Alafenamide151$238,599
RezdiffraResmetirom24$90,651
Entecavir120$47,114
Ursodiol241$40,011
Tacrolimus248$29,616
Mycophenolate Mofetil62$11,912
EliquisApixaban17$10,198
PrografTacrolimus19$10,163
Mycophenolic AcidMycophenolate Sodium27$5,047
Lactulose72$4,029
Valganciclovir Hcl22$3,602
Budesonide EcBudesonide21$3,425
Budesonide DrBudesonide15$2,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadEpclusa, Vemlidy$590$660,740169 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$198$402,504122 claims
Madrigal PharmaceuticalsRezdiffra$56,845$90,65124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →